Trial Profile
A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 1656 (Primary) ; Glipizide
- Indications Type 2 diabetes mellitus
- Focus Pharmacogenomic; Therapeutic Use
- 04 Dec 2012 Planned number of patients changed from 530 to 540 as reported by European Clinical Trials Database.
- 08 Dec 2011 Results presented at the 21st World Diabetes Congress.
- 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.